Compare CVS Health Corp (CVS) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Xylem, Inc. — how do they compare? CVS Health Corp trades at $104.74 (market cap $135.48B), while Xylem, Inc. trades at $121.09 (market cap $28.89B). The key difference: CVS Health Corp is far larger — about 4.7× Xylem, Inc.'s market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | XYL | |
|---|---|---|
Market Cap | $135.48B | $28.89B |
Sector | Health | Industrials |
52-Week High | $106.18 | $152.95 |
52-Week Low | $58.75 | $106.34 |
Enterprise Value | $202.02B | $30.14B |
Dividend Yield | 2.51% | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
XYL trades at $121.21, showing minimal daily change. The stock maintains a bullish technical outlook with consistent earnings beats in recent quarters. Revenue grew to $9.04B in 2025 with a net margin of 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing growth in water technology solutions. Analyst consensus is mixed with a $153.14 price target suggesting 26% upside from current levels.
XYL offers solid fundamentals with expanding profitability and strong cash flow generation. Key risks include execution of growth initiatives and macroeconomic sensitivity. The stock presents a compelling opportunity for long-term investors seeking exposure to essential water infrastructure, though near-term volatility may persist around earnings announcements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
